PT. RICHMOND, Calif., Feb. 7 Transcept Pharmaceuticals,Inc. today announced that Glenn A. Oclassen, Chief Executive Officer &President, will present at the 10th Annual BIO CEO & Investor Conference atthe Waldorf-Astoria Hotel in New York City on Tuesday, February 12, 2008 at10:15 AM Eastern Time.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical companyderiving significant new patient benefits from proven CNS drugs. Transceptdevelopment projects leverage new understanding of CNS conditions to provideadditional uses and enhanced clinical benefits for existing active agents. Thelead Transcept product, Intermezzo(R) (zolpidem tartrate lozenge), is a lowdose sublingual formulation of zolpidem for the treatment of insomnia inpatients who awaken in the middle of the night and have difficulty returningto sleep. Phase 3 clinical trials have been completed for Intermezzo(R) andTranscept plans to submit an NDA in the third quarter of 2008. Anotherproduct being developed by Transcept is TO-2060, a novel, fixed-dosecombination of olanzapine and ondansetron for the treatment of dopamineassociated psychiatric disorders. TO-2060 has recently completed a successfuldose ranging trial for the treatment of alcohol use disorder and a fullclinical development program has begun. For further information, please visitthe company's website at: http://www.transcept.com.Contacts: Transcept Pharmaceuticals, Inc. Michael Gill Director of Communications (510) 215-3575 [email protected]
The Ruth Group Investors / Media Stephanie Carrington / Jason Rando (646) 536-7017 / 7025 [email protected] [email protected]
SOURCE Transcept Pharmaceuticals, Inc.